Drug Profile


Alternative Names: BB 3644

Latest Information Update: 18 Feb 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator British Biotech
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Metalloprotease inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 06 Aug 2003 Discontinued - Preclinical for Inflammatory bowel disease in United Kingdom (PO)
  • 06 Aug 2003 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (PO)
  • 11 Oct 2001 Rights to solimastat have been returned to British Biotech by Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top